What is SOT ? SOT is Supportive Oligonucleotide Therapy.
Supportive oligonucleotide therapy is an advanced, personalised form of cancer treatment that disrupts how cancer cells replicate or survive. Specifically, SOTs use a modified specific type of RNA, known as short interfering RNAs (siRNAs), that binds to a specific gene, essential for survival or replication of cancer cells. SOTs target cancer cells in the body, preventing cancer from growing or spreading. SOT is also used in our practice for Lyme Disease and related Tick Infections in addition to cancer
A newly published study by RGCC scientists has found that cancer patients treated with the highly targeted supportive oligonucleotide therapy (SOT) showed benefits in 77% of cases.
SOT is an advanced, personalized form of cancer treatment that disrupts how cancer cells replicate or survive. RGCC scientists have found that cancer patients treated with the highly targeted SOT showed benefits in 77% of cases. A new paper published in the in vivo journal finds evidence that SOTs effectively target and kill cancer cells on their own or in tandem with other therapies.
Our research team are optimistic about the impact of their findings. “We showed that the use of SOTs in cancer can be very beneficial for patients.” Furthermore, “siRNA molecules are safe and specific on targeting, therefore can be used in cases where other drugs cannot.”
Some cancers appeared to respond better to treatment with SOTs, results suggest. The team found a higher response in patients with leukaemia (100%), prostate cancer (95.00%), colorectal cancer (88.00%), and breast cancer (81.00%). No adverse side effects were noted in the paper, which suggests that patients of any age well tolerate SOT treatment.
You most discuss SOT with your health care practitioner.
Until tomorrow…